Compare TG Therapeutics Inc (TGTX) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs WD 40 Company — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while WD 40 Company trades at $202.29 (market cap $2.73B). The key difference: TG Therapeutics Inc is far larger — about 3× WD 40 Company's market cap, and WD 40 Company pays a 2% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and WD 40 Company for 22 Days on average.
| TGTX | WDFC | |
|---|---|---|
Market Cap | $8.16B | $2.73B |
Volume | 1,735,121 | 130,665 |
Sector | Health | Basic Materials |
52-Week High | $59.06 | $264.91 |
52-Week Low | $26.94 | $187.52 |
Typical Hold Time | 16 Days | 22 Days |
Enterprise Value | $8.37B | $2.79B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
WDFC trades at $202.29, showing modest daily gains. The technical outlook is bullish, supported by moving averages, while recent earnings have largely beaten expectations. The company maintains strong profitability with a 13.22% net income margin and a 33.22% ROE, though valuation multiples like a P/E of 30.96 appear elevated. Positive news highlights strategic growth initiatives and institutional buying interest.
The stock presents a mixed outlook; robust fundamentals and growth strategy support upside, but high valuation and margin pressures from input costs pose risks. Analyst consensus is cautious with a majority hold rating, indicating balanced but not aggressive investor sentiment near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
